be used as a standard for this genetic testing in the pediatric population. 2 
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Response to Saul
To the Editor: We understand the concern raised by Dr Saul 1 that a fragile X analysis is not included along with a microarray in the testing algorithm for the categories of "multiple nonspecific concerns, " "autism and intellectual disability, " and "no gene panel available" (Figure 1 ) of our recent publication. 2 The algorithm refers to clinical problems in addition to intellectual disability and autism. Fragile X testing is discussed twice in the text as first-tier molecular testing for autism and intellectual disability. Furthermore, in Figure 1 , suspicion of a triplet-repeat disorder (such as fragile X) should prompt a triplet-repeat analysis. Our article was intended to inform clinicians on how to select from among the often confusing variety of available molecular testing options. The algorithm is not presented as a formal guideline. Other papers, including a guideline from the American College of Medical Genetics and Genomics, are more comprehensive and appropriate for specific clinic problems such as intellectual disability and autism. 
